Antares Pharma Pops Up 11% (SPPI, TEU, ATRS, KEQU, LMNX)

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) stock increased 0.89% to $17.09 in the morning hour after the company announced today that an overview of the Company's business strategy will be given at the 2012 JMP Securities Healthcare Conference being held at The Peninsula Hotel in New York City. The Spectrum Pharmaceuticals presentation is at 3:30pm Eastern Time on Thursday, July 12, 2012.

Additionally, on July 6, 2012, Spectrum Pharmaceuticals Inc and Allos Therapeutics, Inc. announced that Spectrum has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash.

Box Ships Inc (NYSE:TEU) shares fell 1.07% to $8.32 in the early hour. On July 5, 2012, the company announced that it took delivery of its ninth vessel, the OOCL China, a 5,344 TEU Post-Panamax containership built in 1996 at the Samsung shipyard in Korea. The vessel is chartered to Orient Overseas Container Lines Ltd. for a period of thirty-six months plus or minus thirty days at a net daily rate of US$26,465.

Antares Pharma Inc (NASDAQ:ATRS) shares climbed 10.80% to $4.73 in the morning hour. On July 2, 2012, the company announced the appointment of Jonathan S. Jaffe MD to the position of Vice President of Clinical Development. Jonathan's background includes a 12 year post-graduate career in academic medicine and over 15 years of experience in global drug development in the pharmaceutical industry. 

Kewaunee Scientific Corporation (NASDAQ:KEQU) stock gained 3.90% to $12.53 in the early hour. The company posted a sharp increase in profit for the fourth quarter, owing to higher revenues. The company reported fourth quarter net profit of $1.26 million or $0.49 per share, as compared to $252 thousand or $0.10 per share in the same quarter last year.  Total revenues for the quarter grew 8% to $28.99 million from $26.95 million in the prior-year quarter.

Luminex Corporation (NASDAQ:LMNX) shares plunged 12.48% to $21.31 in the early hour after the company announced a definitive agreement to acquire privately-held, GenturaDx, a molecular diagnostics company. The integration of Luminex's MultiCode-RTx chemistry with the GenturaDx instrument is expected to result in a market leading system for molecular diagnostic testing.